Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 1
2017 2
2018 2
2020 2
2021 1
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Gastroesophageal Junction Adenocarcinoma"
Page 1
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A, Khan U, King DA, Klute K, Lacy J, Lee JJ, Mehta R, Mukherjee S, Nagarajan A, Park H, Saeed A, Semrad TJ, Shitara K, Smyth E, Uboha NV, Vincelli M, Wainberg Z, Rajdev L. Shah MA, et al. J Clin Oncol. 2023 Mar 1;41(7):1470-1491. doi: 10.1200/JCO.22.02331. Epub 2023 Jan 5. J Clin Oncol. 2023. PMID: 36603169
For HER2-negative patients with esophageal or gastroesophageal junction (GEJ) AC and PD-L1 CPS 5, first-line therapy with nivolumab and CT is recommended. ...For patients with advanced gastroesophageal or GEJ AC whose disease has progressed after first-line t …
For HER2-negative patients with esophageal or gastroesophageal junction (GEJ) AC and PD-L1 CPS 5, first-line therapy with nivo …
Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.
Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP, Kuipers EJ, Spaander MC. Janmaat VT, et al. Cochrane Database Syst Rev. 2017 Nov 28;11(11):CD004063. doi: 10.1002/14651858.CD004063.pub4. Cochrane Database Syst Rev. 2017. PMID: 29182797 Free PMC article. Review.
BACKGROUND: Almost half of people with esophageal or gastroesophageal junction cancer have metastatic disease at the time of diagnosis. ...Based on this meta-analysis, palliative chemotherapy and/or targeted therapy can be considered standard care for esophag …
BACKGROUND: Almost half of people with esophageal or gastroesophageal junction cancer have metastatic disease at the ti …
Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
Grizzi G, Petrelli F, Di Bartolomeo M, Viti M, Texeira Moraes M, Luciani A, Passalacqua R, Ghidini M, Tomasello G, Baiocchi GL, Celotti A. Grizzi G, et al. Gastric Cancer. 2022 Sep;25(5):982-987. doi: 10.1007/s10120-022-01314-9. Epub 2022 Jun 15. Gastric Cancer. 2022. PMID: 35704113
INTRODUCTION: Currently, the standard treatment for gastric and gastroesophageal junction (GEJ) adenocarcinoma, including distal esophagus, consists of perioperative chemotherapy (CT) according to FLOT schedule (5FU/leucovorin/oxaliplatin and docetaxel), or o …
INTRODUCTION: Currently, the standard treatment for gastric and gastroesophageal junction (GEJ) adenocarcinoma, includi …
Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review.
Gupta V, Coburn N, Kidane B, Hess KR, Compton C, Ringash J, Darling G, Mahar AL. Gupta V, et al. J Thorac Cardiovasc Surg. 2018 Aug;156(2):847-856. doi: 10.1016/j.jtcvs.2018.03.146. Epub 2018 Apr 12. J Thorac Cardiovasc Surg. 2018. PMID: 30011772 Free article.
RESULTS: We identified 16 prognostication tools for patients treated with curative intent and 1 for patients with metastatic disease. These tools frequently excluded adenocarcinoma, contained outdated data, and were developed with a limited sample size. ...
RESULTS: We identified 16 prognostication tools for patients treated with curative intent and 1 for patients with metastatic disease. …
Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
Zhang X, Zhou L, Zhou C, Shen L. Zhang X, et al. Adv Ther. 2024 Jun;41(6):2112-2132. doi: 10.1007/s12325-024-02838-5. Epub 2024 Apr 15. Adv Ther. 2024. PMID: 38619719 Free PMC article. Review.
The efficacy and safety of ramucirumab (RAM) monotherapy or in combination with paclitaxel (PTX) for patients with unresectable advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEA) have been established in clinical trials. .. …
The efficacy and safety of ramucirumab (RAM) monotherapy or in combination with paclitaxel (PTX) for patients with unresectable advanced or …
Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Jensen K; GE Adenocarcinoma Meta‐analysis Group. Ronellenfitsch U, et al. Cochrane Database Syst Rev. 2013 May 31;(5):CD008107. doi: 10.1002/14651858.CD008107.pub2. Cochrane Database Syst Rev. 2013. PMID: 23728671 Review.
BACKGROUND: The outcome of patients with locally advanced gastroesophageal adenocarcinoma (adenocarcinoma of the esophagus, gastroesophageal (GE) junction, and stomach) is poor. ...AUTHORS' CONCLUSIONS: Perioperative chemotherapy for resectable …
BACKGROUND: The outcome of patients with locally advanced gastroesophageal adenocarcinoma (adenocarcinoma of the esopha …
Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y, Sternschuss M, Moore A, Perl G, Brenner B, Goldvaser H. Kundel Y, et al. Cancer Med. 2020 Oct;9(20):7613-7625. doi: 10.1002/cam4.3417. Epub 2020 Sep 1. Cancer Med. 2020. PMID: 32869544 Free PMC article.
BACKGROUND: Efficacy of immune checkpoint inhibitors (ICIs) in metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma is inconsistent. ...METHODS: We identified randomized controlled trials (RCTs) that compared standard treatment for meta …
BACKGROUND: Efficacy of immune checkpoint inhibitors (ICIs) in metastatic gastric/gastroesophageal junction (GEJ) ad …
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.
Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Vellayappan BA, et al. Cochrane Database Syst Rev. 2017 Aug 22;8(8):CD010511. doi: 10.1002/14651858.CD010511.pub2. Cochrane Database Syst Rev. 2017. PMID: 28829911 Free PMC article. Review.
The primary outcome was overall survival (OS), estimated with Hazard Ratio (HR). Secondary outcomes, estimated with risk ratio (RR), were local and distant progression-free survival (PFS), quality of life (QoL), treatment-related mortality and morbidity, and use of salvage …
The primary outcome was overall survival (OS), estimated with Hazard Ratio (HR). Secondary outcomes, estimated with risk ratio (RR), …
Status and prognosis of lymph node metastasis in patients with cardia cancer - a systematic review.
Okholm C, Svendsen LB, Achiam MP. Okholm C, et al. Surg Oncol. 2014 Sep;23(3):140-6. doi: 10.1016/j.suronc.2014.06.001. Epub 2014 Jun 11. Surg Oncol. 2014. PMID: 24953457 Review.
BACKGROUND: Adenocarcinoma of the gastroesophageal junction (GEJ) has a poor prognosis and survival rates significantly decreases if lymph node metastasis is present. ...A systematic review of English publications dealing with adenocarcinoma of the car …
BACKGROUND: Adenocarcinoma of the gastroesophageal junction (GEJ) has a poor prognosis and survival rates significantly …
Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
de Moraes FCA, Pasqualotto E, Chavez MP, Ferreira ROM, De Castria TB, Burbano RMR. de Moraes FCA, et al. BMC Cancer. 2024 Feb 21;24(1):240. doi: 10.1186/s12885-024-11980-w. BMC Cancer. 2024. PMID: 38383390 Free PMC article.
BACKGROUND: The benefit of adding Zolbetuximab to the treatment in patients with Claudin-18 isoform 2 (CLDN18.2)-positive, human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenoc …
BACKGROUND: The benefit of adding Zolbetuximab to the treatment in patients with Claudin-18 isoform 2 (CLDN18.2)-positive, human epidermal g …
14 results